Toolkit Developed for Diagnosis and Management of Menopause
|
By LabMedica International staff writers Posted on 04 Aug 2014 |
A simple toolkit designed to help general practitioners (GP) diagnose and manage menopause is now available free of charge.
Created at Monash University (VIC, Australia), the "Practitioner Toolkit for Managing the Menopause" is the world’s first such kit, designed for GPs to use with women from the age of 40. The research team, led by Prof. Susan Davis, combined existing research on menopause, diagnostic algorithms, and extensive clinical experience to develop the diagnostic tool. It also helps the GP work through a patient’s medical history and risk factors to arrive at an optimal solution.
The toolkit fills the void of clear guidelines on diagnosis and management, equipping primary-care physicians, as well as nurses, with the fundamentals to provide more effective care for women. “There are many detailed guidelines available on menopause but the reality is that most GPs don’t have the time to work through a 40 page report [...] with a patient,” said Prof. Davis, “Based on feedback from patients and doctors we realized there’s widespread confusion." Also, "With many recent medical graduates receiving little training in this area, we realized there was a clear need for simple and practical guidelines,” she added.
Menopausal symptoms vary widely from none at all to debilitating, making a straightforward diagnosis difficult. "Every woman has her own individual experience of menopause and that sometimes makes it tricky to diagnose," said Prof. Davis. The kit includes a flow chart of standardized questions for doctors to ask in a routine consultation to help identify women who may be entering menopause. The kit also flags safety concerns, provides a list of hormone therapies approved by regulators in different countries, and lists non-hormonal therapies that have evidence to support their use. It also helps inform on benefits and risks of menopausal treatments. The kit is designed to work as well for a woman of age 41 in Madras as for one of age 48 in Manhattan, and the International Menopause Society is promoting its global use, stating that it is the first to present structured practical advice.
Jane Elliott, MD, said the toolkit was clear and accessible, making it ideal to use in GP consultations. Dr. Anna Fenton, a leading endocrinologist and president of the Australasian Menopause Society, also welcomed and recommended the toolkit: “In an area fraught with myths and misinformation, this toolkit provides concise and accurate information. The key messages are clear and the advice is practical and evidence-based,” said Dr. Fenton.
The paper on the kit was published online July 6, 2014, in the journal Climacteric.
Related Links:
Monash University
Menopause Toolkit for GPs
Created at Monash University (VIC, Australia), the "Practitioner Toolkit for Managing the Menopause" is the world’s first such kit, designed for GPs to use with women from the age of 40. The research team, led by Prof. Susan Davis, combined existing research on menopause, diagnostic algorithms, and extensive clinical experience to develop the diagnostic tool. It also helps the GP work through a patient’s medical history and risk factors to arrive at an optimal solution.
The toolkit fills the void of clear guidelines on diagnosis and management, equipping primary-care physicians, as well as nurses, with the fundamentals to provide more effective care for women. “There are many detailed guidelines available on menopause but the reality is that most GPs don’t have the time to work through a 40 page report [...] with a patient,” said Prof. Davis, “Based on feedback from patients and doctors we realized there’s widespread confusion." Also, "With many recent medical graduates receiving little training in this area, we realized there was a clear need for simple and practical guidelines,” she added.
Menopausal symptoms vary widely from none at all to debilitating, making a straightforward diagnosis difficult. "Every woman has her own individual experience of menopause and that sometimes makes it tricky to diagnose," said Prof. Davis. The kit includes a flow chart of standardized questions for doctors to ask in a routine consultation to help identify women who may be entering menopause. The kit also flags safety concerns, provides a list of hormone therapies approved by regulators in different countries, and lists non-hormonal therapies that have evidence to support their use. It also helps inform on benefits and risks of menopausal treatments. The kit is designed to work as well for a woman of age 41 in Madras as for one of age 48 in Manhattan, and the International Menopause Society is promoting its global use, stating that it is the first to present structured practical advice.
Jane Elliott, MD, said the toolkit was clear and accessible, making it ideal to use in GP consultations. Dr. Anna Fenton, a leading endocrinologist and president of the Australasian Menopause Society, also welcomed and recommended the toolkit: “In an area fraught with myths and misinformation, this toolkit provides concise and accurate information. The key messages are clear and the advice is practical and evidence-based,” said Dr. Fenton.
The paper on the kit was published online July 6, 2014, in the journal Climacteric.
Related Links:
Monash University
Menopause Toolkit for GPs
Latest Clinical Chem. News
- Blood-Based Alzheimer’s Testing Platform Offers Rapid Results
- Maternal Blood Biomarkers Identify Risk of Preterm and Early-Term Birth
- Simple Oral Swab Monitors Persistent Inflammation in Primary Ciliary Dyskinesia
- Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features
- Plasma Vitamin C Levels Associated with Brain Structure and Connectivity in Aging
- Mass Spectrometry Detects Tumor Metabolites for Cancer Monitoring
- Urinary Biomarker Assay Predicts Kidney Disease Progression Beyond Standard Measures
- Saliva-Based Test Detects Biochemical Signs of Sleep Loss
- Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
- Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
- Urine-Based Test Shows Promise for Autism Screening in Children
- Blood-Based Sensor Detects Early Signs of Alzheimer’s and Parkinson’s
- Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
- Urine-Based Alzheimer’s Test Receives FDA Breakthrough Device Designation
- Fluid Biomarker Improves Diagnosis and Monitoring of Primary CNS Lymphoma
- New CA19-9 Cutoff Value Helps Identify High-Risk Pancreatic Cancer Patients
Channels
Molecular Diagnostics
view channel
Point-of-Care PCR Panel Detects RSV, Influenza, and SARS-CoV-2 in Minutes
Respiratory syncytial virus, influenza, and SARS-CoV-2 remain major respiratory pathogens in ambulatory care. RSV is a particular priority because it can cause significant disease in infants, older adults,... Read more
Whole-Genome Sequencing Enables Genetic Diagnosis in Neurodevelopmental Disorders
Neurodevelopmental disorders include autism spectrum disorder and intellectual disability and can be difficult to diagnose because clinical presentations vary widely. In Italy, approximately 1% of children... Read more
Genetic Testing Identifies High-Risk Patients with Inflammatory Bowel Disease
Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn’s disease, is a lifelong, unpredictable condition that can require advanced therapies or surgery. More than half a million people in the U.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Antibody Profiles Provide Clues to Long COVID Severity and Symptoms
Persistent symptoms after acute COVID-19 affect millions of people, causing fatigue, respiratory issues, and cognitive deficits that can be difficult to quantify with standard tests. Clinical teams lack... Read moreAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread
Melioidosis, a potentially fatal infection caused by Burkholderia pseudomallei, remains difficult to recognize because its symptoms can mimic tuberculosis and other illnesses. The disease is considered... Read more
Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
Helicobacter pylori infects an estimated 43.9% of the global population, affecting approximately 4.4 billion people worldwide. In many regions, including Africa, Eastern Europe, and Southeast Asia, prevalence... Read more
Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE
Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read morePathology
view channel
Stain-Free Imaging Platform Matches Standard Cancer Pathology
Histopathology underpins cancer diagnosis, but turnaround times and inter-laboratory variability can limit timely, consistent interpretation. Conventional staining relies on chemical dyes and multiple... Read more
New Companion Diagnostic Expands Precision Medicine in Prostate Cancer
Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools
QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more








